Gainers
- Plus Therapeutics (NASDAQ:PSTV) stock rose 101.5% to $1.11 during Thursday's pre-market session. The company's market cap stands at $25.5 million.
- Curis (NASDAQ:CRIS) stock moved upwards by 36.19% to $1.43. The company's market cap stands at $131.2 million.
- ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 18.28% to $0.89. The company's market cap stands at $28.7 million. As per the press release, Q2 earnings came out 3 days ago.
- OncoCyte (NASDAQ:OCX) stock rose 14.4% to $1.0. The company's market cap stands at $118.6 million.
- Rigel Pharmaceuticals (NASDAQ:RIGL) shares moved upwards by 13.13% to $1.8. The company's market cap stands at $310.8 million.
- bluebird bio (NASDAQ:BLUE) stock increased by 11.06% to $7.53. The company's market cap stands at $580.7 million.
Losers
- Blue Water Vaccines (NASDAQ:BWV) shares decreased by 31.8% to $5.21 during Thursday's pre-market session. The market value of their outstanding shares is at $71.1 million. The company's, Q2 earnings came out 3 days ago.
- Unity Biotechnology (NASDAQ:UBX) shares decreased by 31.16% to $0.67. The market value of their outstanding shares is at $46.5 million. As per the news, the Q2 earnings report came out 4 days ago.
- Accelerate Diagnostics (NASDAQ:AXDX) shares decreased by 21.06% to $2.7. The market value of their outstanding shares is at $220.2 million. As per the news, the Q2 earnings report came out 3 days ago.
- Eargo (NASDAQ:EAR) shares decreased by 15.02% to $2.66. The market value of their outstanding shares is at $104.7 million.
- Histogen (NASDAQ:HSTO) stock decreased by 13.83% to $1.87. The company's market cap stands at $4.6 million.
- Quoin Pharmaceuticals (NASDAQ:QNRX) shares declined by 11.5% to $4.85. The company's market cap stands at $17.6 million. As per the press release, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
